Bone-Directed Treatments for Prostate Cancer

Saad, Fred

doi:10.1016/j.hoc.2006.03.011

Cited by 16 publications

(2 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients who started BHAs early had lower incidence rates of EBRT and also of other SSEs, but the incidence of other SSEs was low in our population (<10%). Our results on spinal cord compressions are similar to other studies, but we observed less pathologic fractures (3% vs 25%) [39]. We only captured symptomatic skeletal complications (SSEs) and not SREs which also include asymptomatic fractures on protocol mandated radiologic assessment.…”

Section: Discussionsupporting

confidence: 88%

Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands

Kuppen

Westgeest

Eertwegh

et al. 2022

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 88%

Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands

Kuppen

Westgeest

Eertwegh

et al. 2022

Clinical Genitourinary Cancer

View full text Add to dashboard Cite

“…At present, the issue of controlling the early metastasis of bone neoplasms has become a bottleneck in the treatment of this disease [3,4]. Although many therapeutic protocols such as surgical therapy, chemoradiotherapy, and immunotherapy have been applied in bone neoplasms patients, the prognosis of clinical patients remains poor for short of effective therapeutic targets [5][6][7][8][9].…”

Section: Introductionmentioning

confidence: 99%

miRNA-128 modulates bone neoplasms cells proliferation and migration through the WNT/β-catenin and EMT signal pathways

Long

Wang

et al. 2021

J Orthop Surg Res

View full text Add to dashboard Cite

Background Bone neoplasms present poor prognosis due to recurrence and metastasis. Although the role microRNAs (miRNAs) in inhibiting growth and metastasis of bone neoplasms has been investigated, the underlying potential molecular mechanisms mediated by miRNA-128 (miR-218) for the invasiveness of bone neoplasms cells are still not completely understood. The purpose of this study was to identify the regulatory mechanisms of miR-218 in bone neoplasms cells. Methods Western blotting, quantitative reverse transcription-polymerase chain reaction (qRT-PCR), Counting Kit-8 assay, terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) staining, luciferase activity assay immunofluorescence, and immunohistochemistry were used to analyze the regulatory effects of miR-218 on bone neoplasms cells. Results Here, the results showed that transfection of miR-128 suppressed bone neoplasms cells proliferation, migration, and invasion. Genetic knockdown of miR-128 in bone neoplasms cells suppressed the activation of the Wnt/β-catenin and epithelial-mesenchymal transition (EMT) signaling pathways. Activation of Wnt or EMT blocked miR-128-inhibited cells proliferation and migration in bone neoplasms cells. Exogenously introduced miR-128 markedly inhibited tumor regeneration in bone neoplasms xenograft models. Conclusions These results define a tumor-regulated function for miR-128 in bone neoplasms by down-regulation of the Wnt/β-catenin and EMT signal pathways, which provided a potential target for bone neoplasms gene therapy.

show abstract

Schmerztherapie von Skelettmetastasen mittels ionisierender Strahlung

Adamietz¹,

Schmidberger²

2011

Praktische Schmerztherapie

View full text Add to dashboard Cite

Bone-Directed Treatments for Prostate Cancer

Cited by 16 publications

References 55 publications

Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands

Symptomatic Skeletal Events and the Use of Bone Health Agents in a Real-World Treated Metastatic Castration Resistant Prostate Cancer Population: Results From the CAPRI-Study in the Netherlands

miRNA-128 modulates bone neoplasms cells proliferation and migration through the WNT/β-catenin and EMT signal pathways

Schmerztherapie von Skelettmetastasen mittels ionisierender Strahlung

Contact Info

Product

Resources

About